Drug updated on 10/29/2024
| Dosage Form | Injection (intravenous; 15.5 MBq/mL to 308.2 MBq/mL [0.42 mCi/mL to 8.33 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS)
- Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Fluorodopa F 18 PET (positron emission tomography) scans revealed significantly decreased uptake in the putamen and caudate nucleus for juvenile Parkinsonism (JP) patients, indicating its effectiveness in identifying dopaminergic deficits associated with this condition.
- In dopamine responsive dystonia (DRD) patients, Fluorodopa F 18 PET scans showed results comparable to normal subjects, with only a slight decrease in uptake in the putamen and caudate nucleus, suggesting limited effectiveness in differentiating DRD from normal conditions.
- The effectiveness of Fluorodopa F 18 PET scans is markedly different between JP and DRD populations, with clear dopaminergic deficits in JP patients versus near-normal results in DRD patients.
- There is no safety information available in the reviewed studies.
- The findings indicate that Fluorodopa F 18 PET scans effectively identify juvenile Parkinsonism (JP) in young patients by showing decreased uptake in the putamen and caudate nucleus, while in dopamine responsive dystonia (DRD) patients, the scans show minimal changes compared to normal subjects, making diagnosis less definitive. Additionally, Parkinson's disease (PD) patients undergoing sham surgery demonstrated placebo-related motor function improvements without corresponding dopaminergic changes as measured by Fluorodopa F 18 PET scans.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Fluorodopa F 18 (fluorodopa f 18) Prescribing Information. | 2019 | The Feinstein Institutes for Medical Research, Manhasset, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Relevance of Fluorodopa PET Scan in Dopamine Responsive Dystonia and Juvenile Parkinsonism: A Systematic Review | 2022 | Neurology International |
| The Placebo Response in Double-Blind Randomised Trials Evaluating Regenerative Therapies for Parkinson's Disease: A Systematic Review and Meta-Analysis | 2022 | Journal of Parkinson's Disease |